Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?

Table 1 Pharmacodynamic parameters based on anti-Xa measurements ^* after single-dose subcutaneous administration in 12 healthy volunteers

	Average MW	Dose	AUC^a	t_½ ^a	Clearance^a,b
	(Da)	(IU)	(h · IU/mL)	(h)	(mL/min)
Enoxaparin	4,400	4,000	3.47 ± 0.69	4.28 ± 1.06	19.2
Dalteparin	5,700	5,000	3.17 ± 0.82	2.31 ± 0.60	26.3
Dalteparin	5,700	5,000	3.23 ± 0.85	2.45 ± 0.66	25.8
Tinzaparin	6,500	3,000	1.35 ± 0.39	2.97 ± 1.01	37.0
UFH	12,000–15,000	5,000	1.33 ± 0.70	–	62.7

^aTwo values are reported for dalteparin since the dosing was repeated to give a measure of the intra-individual variation; ^bCl/F (clearance relative to bioavailability), calculated from data in the publication.
^*Clinical data were extracted from Eriksson et al 1995 [35] and compiled specifically for this review (MW data from Schroeder et al 2011 [31]).

ISSN: 2162-3619